you accept all cookies and can browse the site with a more personalized experience A equipa vencedora da edição de 2024 do Cantanhede Innovation Days CareMinder is the name of a new project that aims to prevent hospital-acquired infections by developing a sensor that uses vibration to remind healthcare workers to regularly disinfect their hands The project was declared the winner of the 7th edition of Cantanhede Innovation Days (Cantanhede i-Days) organised by the University of Coimbra (UC) between 30 October and 6 November will represent UC at the Innovation Days (i-Days) final in Budapest They will also receive a €1,000 prize sponsored by Basinnov Life Sciences The i-Days initiative is an annual event organised by the EIT Health Network involving institutions from 16 countries: Bulgaria Its aim is to challenge students from different academic disciplines to work together to develop innovative solutions to real-world health challenges For the 2024 edition of the Cantanhede Innovation Days the UC student community was challenged to address seven issues faced by healthcare institutions in the central region: remote health monitoring systems for patients monitoring and prevention of hospital-acquired diseases decision support systems for healthcare professionals Participants worked together to develop innovative solutions to one of these challenges over the course of one week lecturers and health professionals to develop their proposals and took part in training sessions on innovation which were evaluated by a jury made up of representatives from education research and health institutions in Coimbra and Cantanhede at the competition final held at the Stone Museum in Cantanhede The Cantanhede i-Days initiative is organised by the R&D International Networks Unit of the University of Coimbra the Centre for Neurosciences and Cell Biology of the UC Rovisco Pais Hospital and the Coimbra Local Health Unit More information about the i-Days initiative is available at https://eithealth.eu/programmes/i-days/. Portugal (Reuters) - Famous for its roasted suckling pig and wines the Portuguese city of Cantanhede now hosts the country's first medical cannabis production farm - a budding European hub of efforts to meet growing demand for the flowering herb.Portugal's California-like weather caught the eye of Canada-based Tilray as its CEO Brendan Kennedy roved around Europe from 2015 to 2017 in search of the perfect spot for a new production site.Kennedy said Portugal had the ideal climate for cannabis cultivation and the country's young educated workforce and its major agricultural sector were further attractions.Covering 2.4 hectares (5.9 acres) in a biotechnology park just outside Cantanhede Tilray's site was given the green light by Portugal's regulator Infarmed in 2017 The company then rushed to import its first baby plants and recently reported its first two successful cannabis harvests.Kennedy opened the site to visitors for the first time at a ribbon-cutting ceremony on Wednesday."Some of our competitors are located in Denmark and northern Germany where there isn't that much sun - so we think we can produce a more environmentally-friendly product here," he told Reuters.Portugal also offers tariff-free entry to the rest of the European Union a market Tilray wants to explore further at a time when an increasing number of governments are legalising medical marijuana.FROM PROHIBITION TO LEGALISATION"The paradigm is shifting from prohibition to legalisation," Kennedy said "I'm fairly optimistic that over the next two years we will see every country in Europe legalising it."Last year Portugal's parliament approved a bill to legalise marijuana-based medicines following in the footsteps of EU countries such as Italy and Germany as well as Canada and parts of the United States Britain made a similar move in July 2018.Tilray's 20-million-euro ($22.29 million) facility includes indoor packaging and distribution sites for medical cannabis and cannabinoid-derived products.Tilray supplies medical cannabis products with CBD and THC to patients in a number of countries and through agreements with pharmaceutical distributors.Earlier this year the European Parliament called for an EU-wide policy on medical cannabis and properly funded scientific research."We are at point where almost every doctor around the world recognises the medical benefits of cannabis," Kennedy said.The World Health Organization has stated that several studies have demonstrated cannabinoids provide therapeutic effects for nausea and vomiting in the advanced stages of illnesses such as cancer and AIDS.Moreover a handful of regulated pharmaceuticals use chemicals derived from cannabis such as GW Pharmaceuticals' Sativex which is approved for treating symptoms of multiple sclerosis.BOOST EXPORTSFrom Canada the company already sells medical cannabis products to 13 countries Portugal will help Tilray boost exports further Kennedy said."Our business plan for this facility is focused on exporting products from Portugal to other countries around the world."In Europe Tilray products are already available in Germany Cyprus and the Czech Republic but it expects to start exporting to the United Kingdom - and potentially to France Italy and Greece - in the next 12 months.Kennedy said Tilray hopes this summer to expand exports to countries such as South Africa Australia and New Zealand.According to analysis firm Prohibition Partners the EU cannabis market will be worth 123 billion euros by 2028.Kennedy did not confirm how much medical marijuana Tilray plans to produce.($1 = 0.8973 euros)Reporting by Catarina Demony and Rafael Marchante; Editing by Mark Heinrich Our Standards: The Thomson Reuters Trust Principles., opens new tab , opens new tab Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts. , opens new tabScreen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. © 2025 Reuters. All rights reserved Canadian cannabis producer Tilray is investing about $29.5 million in a medical cannabis operation in Portugal a company certified in medical cannabis research and production has secured all the licenses to export cannabis seeds and clones to be cultivated at the Biocant Research Park The operation will process and package medical cannabis products for distribution across the European Union and will create 100 quality jobs involving research “Bringing live plants to Portugal is an important milestone for the company,” Tilray’s CEO “Tilray is proud to bring our medical cannabis research and production expertise to the European Union health care providers and researchers throughout the continent,” he added The facility includes an indoor laboratory and genetics bank and a 3,000 m2 processing facility with the expectation of expanding in the years to come Tilray is a global medical cannabis research leader based out of British Columbia Canada.  On November 8th Tilray announced to the public that they have completely exported medical cannabis from its main hub in Canada to their EU campus in Cantanhede  A pioneer in the research and production of medical cannabis and cannabinoids currently Tilray serves tens of thousands of patients and researchers in seven countries spanning four continents in Australia and New Zealand and Portugal (Tilray Portugal Unipessoal Lda) Metrics details Glioblastoma Multiforme (GBM) is the most frequent and lethal primary brain cancer Due to its therapeutic resistance and aggressiveness Platelet-derived Growth Factor (PDGF) genes have been enrolled as drivers of this tumour progression as well as potential therapeutic targets As detailed understanding of the expression pattern of PDGF system in the context of GBM intra- and intertumoral heterogeneity is lacking in the literature this study aims at characterising PDGF expression in different histologically-defined GBM regions as well as investigating correlation of these genes expression with parameters related to poor prognosis Z-score normalised expression values of PDGF subunits from multiple slices of 36 GBMs alongside with clinical and genomic data on those GBMs patients were compiled from Ivy Glioblastoma Atlas Project – Allen Institute for Brain Science data sets PDGF subunits show differential expression over distinct regions of GBM and PDGF family is heterogeneously expressed among different brain lobes affected by GBM PDGF family expression correlates with bad prognosis factors: age at GBM diagnosis Phosphatase and Tensin Homolog deletion and Isocitrate Dehydrogenase 1 mutation These findings may aid on clinical management of GBM and development of targeted curative therapies against this devastating tumour This is likely to give a poor perspective of how is the tumour molecular panel configured and how its already well-described biomarkers are distributed in each single tumour block which has a direct negative impact on the development of successful targeted therapies To motivate further research on GBM, the Ivy Glioblastoma Atlas Project [© 2015 Allen Institute for Brain Science. Ivy Glioblastoma Atlas Project. Available from: http://glioblastoma.alleninstitute.org/] is a scientific initiative that investigates the expression of selected genes on different histological regions of GBM blocks gathers genomic profile and clinical data of the correspondent patients/donors and publishes this valuable resource in the free-access online platforms of Allen Brain Atlas and Ivy GAP Clinical and Genomic Database PDGF system expression data is compiled from those databases with the aim to characterise these genes distribution in different histological regions of a GBM so that more specific curative strategies against this tumour may be devised PDGF expression is studied regarding clinical parameters that influence life expectancy of GBM patients to evaluate the potential role of those genes as prognostic factors in GBM PDGF family expression patterns on each GBM histological region reveal intratumoral heterogeneity PDGF system expression was evaluated in GBM regions of hyperplastic blood vessels in cellular tumour (a); microvascular proliferation (b); pseudopalisading cells around necrosis (c); perinecrotic zone (d); cellular tumour (e); leading edge (f) and infiltrating tumour (g).*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 PDGF genes are differentially expressed over different histological regions of a GBM Expression pattern along distinct areas of a GBM was assessed for each PDGF system component: PDGFA (a); PDGFB (b); PDGFC (c); PDGFD (d); PDGFRA (e); PDGFRB (f) CT-HBV: Hyperplastic Blood Vessels in Cellular Tumour; CT-MVP: Microvascular Proliferation; CT-PAN: Pseudopalisading Cells around Necrosis; IT: Infiltrating Tumour; LE: Leading Edge; CT: Cellular Tumour *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 Analysis of PDGF genes expression regarding GBM location in the brain: Comparison was made on PDGF family expression between tumours located at left and at right hemispheres (a); PDGF subunits expression was studied on GBMs at temporal lobe (b) PDGF expression correlates with prognostic factors of GBM PDGF system expression was analysed according to prognostic factors of Phosphatase and Tensin Homolog (PTEN) deletion (a,b); Isocitrate Dehydrogenase 1 (IDH1) mutation (c,d) This study presents a broad perspective on the inter- and intratumoral heterogeneity of the PDGF family expression in GBMs along with the potential prognostic significance of these genes expression from analysis of the comprehensive database of the Ivy Glioblastoma Atlas Project – Allen Institute for Brain Science The herein shown correlation between PDGF genes expression and the clinical and genomic prognostic factors aforementioned suggests that those genes should be further considered as additional prognosis markers that may aid clinical management of GBM patients will certainly have a positive effect on implementation of targeted therapy tailored for each patient which greatly increases the chances of changing the current poor prognosis paradigm and reaching curative treatments in the near future the present study contributes to the characterisation of GBM heterogeneity as it reveals that PDGF genes show specific expression patterns through different regions of a GBM as well as differential expression accordingly to the location of the tumour in the brain the PDGF family can also be linked to prognostic factors of the GBM these results should contribute to the realization of personalised medicine towards the development of successful therapeutics against this so common and so devastating tumour clinical and genomic data on 36 primary GBMs and their donors were compiled from two different platforms of Ivy Glioblastoma Atlas Project [© 2015 Allen Institute for Brain Science Available from: glioblastoma.alleninstitute.org] Z-score normalised expression values of PDGF subunits were downloaded from the Anatomic Structures RNA-Sequencing data set of the online Allen Brain Atlas [Available in: glioblastoma.alleninstitute.org/rnaseq/search/index.html Gene expression data available in this open access atlas was obtained by RNA sequencing technique applied to the seven GBM histological structures that were isolated by laser micro-dissection in each histological section of tumour blocks: Leading Edge Hyperplastic Blood Vessels in Cellular Tumour and Microvascular Proliferation All values are described to be processed through post-hoc data normalisation followed by TbT normalisation More detailed description on the methodology of gene expression data production is available on the Technical White Paper: Overview – 2015 accessible in glioblastoma.alleninstitute.org extensive clinical and genomic data of the patients recruited for the study are available in the online Ivy GAP Clinical and Genomic Database [Available in: ivygap.swedish.org/home last access in May 2016] and were gathered and tabulated Gene expression values of PDGF subunits (PDGFA, PDGFB, PDGFC, PDGFD, PDGFRA, PDGFRB) were analysed with regard to variables such as GBM histological structure, clinical parameters and genomic data. GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla California USA (www.graphpad.com) was used for graphical representation and statistical analysis Differences between two sample groups were assessed by Mann-Whitney test whereas multiple comparisons were evaluated by Kruskal-Wallis test followed by Dunn’s Multiple Comparisons test Values were assessed as medians and correlations were considered statistically significant if p value <0.05 The datasets analysed during the current study are from the © 2015 Allen Institute for Brain Science - Ivy Glioblastoma Atlas Project available in: glioblastoma.alleninstitute.org and ivygap.swedish.org/home Glioblastoma multiforme: a look inside its heterogeneous nature Differential Expression of MMAC / PTEN in Glioblastoma Multiforme: Relationship to Localization and Prognosis Advances in Brief Differential Expression of MMAC / PTEN in Glioblastoma Multiforme: Relationship to Localization and Prognosis 1 Download references This work was funded by the Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq PROPESQ-UFPE and the authors are grateful for the genererous donation from Nubia Martins The authors thankfully acknowledge the comprehensive Allen Institute for Brain Science datasets especially the Ivy Glioblastoma Atlas Project Valuable inputs from the post-doctorate researchers Roberta Lemos and Eriton Cunha on data analysis are greatly appreciated Manuscript revision by the cancer biologist Dr Gaëlle Bougeard-Denoyelle provided significant contribution to the refinement of this paper Isabella Gomes Cantanhede & João Ricardo Mendes de Oliveira composed the figures/table and elaborated the manuscript All authors reviewed and revised the manuscript The authors declare that they have no competing interests Download citation DOI: https://doi.org/10.1038/s41598-017-15045-w Anyone you share the following link with will be able to read this content: a shareable link is not currently available for this article Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research BY WILL YAKOWICZ, STAFF WRITER, INC. @WILLYAKOWICZ Tilray, a Canadian cannabis producer owned by Seattle-based Privateer Holdings, is expanding its marijuana production footprint to the European Union which raised €20 million for the expansion is building a growing and production facility in Portugal Tilray says its Portuguese facility will be up and running later this year Tilray, which was one of the first companies to be federally licensed to grow and sell medical marijuana in Canada in 2014 said in a statement that it will break ground on what it’s calling its “European Union campus” by spring of 2018 will be able to legally distribute medical marijuana to medical cannabis programs which will be located in a research park Cantanhede a town two and a half hours north of Lisbon and distribute medical cannabis and THC products to medical marijuana patients and researchers throughout the European market (Portugal decriminalized use of all drugs in 2001.) Construction its a 27,000 square-foot greenhouse and a 3,200 square-foot processing facility will start this month The company said that the new facility will increase its annual global production capacity by five times to 68 tons of cannabis by the end of 2018 Tilray says it will create 100 jobs in Portugal The government of Portugal licensed Tilray to import cannabis seeds into the country and cultivate medical cannabis for the legal medical market last year Brendan Kennedy, the CEO of Tilray and founder of parent company Privateer, which also owns marijuana brand Marley Natural and other marijuana companies says the expansion to Europe is part of a bigger global business move “Tilray’s EU Campus is another strategic milestone as we aim to build the world’s most trusted and admired medical cannabis brand,” Kennedy said in a statement which was one of the first North American companies to export medical marijuana from Canada to the European Union it plans to export cannabis to five other countries its products are available in six countries Refreshed leadership advice from CEO Stephanie Mehta Learn More Please enable JS and disable any ad blocker biotech player CarboCode has closed a €15M ($15.3M) Series C funding round led by Iberis Capital The company has developed a proprietary tech platform for the large-scale production of human-identical breast milk lipids and molecules to supercharge the nutritional attributes of infant formula Naturally present in breast milk and organ membranes It will use the funds to launch a new manufacturing facility hire researchers take its staff count past 50 Founded by Ferenc Horvath and Jorge Santos in 2017 CarboCode is based at the Biotechnology Innovation Center in Biocant Park and specialises in the production of human-identical glycosphingolipids (GSLs) and gangliosides GSLs play a critical role in brain development and cognitive function in infants, and breast milk has been found to be a better source of these lipids than commercially available baby formula regulate cell signalling and are crucial in the maturation of the central nervous system and support a balanced immune response and healthy gut microbiome are largely absent from conventional infant formula products CarboCode synthesises these molecules in their natural form by combining proteins and metabolic engineering with biocatalysis and fermentation it invested €45M to build a new industrial factory in the Cantanhede industrial park which will be able to produce 100 tonnes of gangliosides every year when it begins operating in 2029 The investment was part of an €80M drive to accelerate commercialisation “Access to human-identical gangliosides presents a rare opportunity to make a real positive impact on people’s lives,” said Santos “CarboCode’s technologies enable the production of these compounds driving our commitment to making this dream a short-term reality.” The B2B startup’s initial product line will focus on the absence of gangliosides in formula and it says it will supply ingredients to industry giants like Danone The infant formula market is set to surpass $84B by 2029 CarboCode expects to have an annual turnover exceeding €100M ($102M) the startup is also aiming to target cosmetics As a company producing human-identical breast milk molecules through biotechnology it would need to pass stringent regulatory checks before coming to market The latest capital injection will help the company do so with an aim to secure approval in the EU and the US by 2027 but many more say they’re not producing enough or have nutritional deficiencies in their milk is developing cultivated breast milk with as many constituents as possible) Green Queen is an editorially-driven media publication. Over 98% of our content is editorial and independent. Paid posts are clearly marked as such: look for 'This is a Green Queen Partner Post' at the bottom of the page. Join the conversation You can save this article by registering for free here. Or sign-in if you have an account showing how branding strategies are paying off for some companies in the crowded cannabis space Subscribe now to read the latest news in your city and across Canada Create an account or sign in to continue with your reading experience which leads Canada in cannabis market share on Monday reported fiscal second-quarter earnings before interest topping the average analyst estimate of US$11.3 million Tilray said it was able to maintain profitability in the period ended Nov 30 thanks to demand for its cannabis brands and consumer franchises like SweetWater craft beer and Manitoba Harvest hemp products Tilray seeks to further capitalize on its brand strength by launching a new parent name The name change reflects an “evolution from a Canadian LP to a global consumer packaged goods company powerhouse with a market leading portfolio of cannabis and lifestyle CPG brands,” the company said By signing up you consent to receive the above newsletter from Postmedia Network Inc The next issue of Top Stories will soon be in your inbox Interested in more newsletters? Browse here. The pivot to a brand focus comes at a time when the cannabis industry has grown immensely but there are still few recognizable product names said on a recent earnings call that consumer preferences in Canada’s cannabis market are shifting rapidly and it has struggled to keep up Tilray said its brand strength and adept pricing and marketing have allowed it to maintain share “We do not believe this is a sustainable environment Only the strong will survive,” said Blair MacNeil He said the company plans to focus on more aggressive marketing strategy and its new product pipeline to overcome competitive pressures MacNeil said that inventory levels at a lot of Canadian firms are too high and prices have come down sharply as a result While competitors have recently lowered prices by around 23 per cent Tilray has only lowered its prices by about two per cent leaving it with more flexibility than other companies “The market is getting very diluted,” he said noting that 157 brands were introduced in the last year Tilray also leads in Germany in medical cannabis extracts and dried flower combined Tilray sees Germany poised to legalize recreational use and expects other European countries will follow paring earlier gains of as much as 22 per cent The stock had slumped to start the year and is now up about six per cent so far in 2022 Short interest in Tilray is 11 per cent of available shares according to data from financial analytics firm S3 Partners transmission or republication strictly prohibited This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy You can manage saved articles in your account Canadian cannabis producer Tilray says it will invest 20 million euros (about C$29.5 million) in a medical cannabis operation in Portugal after winning federal licences there to import cannabis seeds and clones and cultivate them It says it plans to establish a campus at Cantanhede process and package medical cannabis products for distribution across the European Union CEO Brendan Kennedy says the licences are the culmination of a two-year search for a location from which to serve demand for cannabis in Europe adding Tilray estimates the market could grow to 10 million patients and generate as much as 40 billion euros per year in revenue "We're seeing massive demand from Germany so we needed to build a large facility to meet that demand and we needed to get it up and running very quickly," he said "And Portugal seemed like the ideal location to grow plants." Kennedy said Tilray is the first company — foreign or domestic — to win a licence to grow cannabis containing the active ingredient THC in Portugal Tilray says its first phase will feature outdoor growing fields plus 108,000 square feet of greenhouses 1,600 square feet of processing facilities located in and around the BIOCANT Research Park in Cantanhede Construction is to start this month and be completed by next spring says it is currently selling products in six countries and plans to begin exports to five more by the end of this year The Portugal operation would be its first outside of Canada Kennedy said the project will likely not initially serve the Portuguese domestic market Read today's Portuguese stories delivered to your email We appreciate that not everyone can afford to pay for our services but if you are able to we ask you to support The Portugal News by making a contribution – no matter how small You can change how much you give or cancel your contributions at any time Send us your comments or opinion on this article Reaching over 400,000 people a week with news about Portugal .st1{fill-rule:evenodd;clip-rule:evenodd;fill:#2a2a2a}By Andrew Dodson | adodson@mlive.comAP PhotoPop star Madonna.BAY CITY — Liz Rosenberg said the pop singer will not issue any statement in regards to the recent death of her maternal grandmother Elsie Mae Fortin but Madonna will not be issuing any statements or conversing with the media regarding her grandmother It is totally a personal matter to her." Rosenberg did not confirm if Madonna is attending the funeral when she died in her home at 404 North Dean St Fortin was reportedly very close with her famous and Bay City-born granddaughter having partially raised her since her mother's death in 1963 died Wednesday just three months shy of her 100th birthday & grandmother Elsie Fortin (on the left) in 1985 of Madonna with her grandmother in 1985 at the premiere of the Like a Virgin tour in Detroit Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement, (updated 8/1/2024) and acknowledgement of our Privacy Policy, and Your Privacy Choices and Rights (updated 1/1/2025) © 2025 Advance Local Media LLC. All rights reserved (About Us) The material on this site may not be reproduced except with the prior written permission of Advance Local Community Rules apply to all content you upload or otherwise submit to this site YouTube's privacy policy is available here and YouTube's terms of service is available here Ad Choices The Retail Mind Group is developing four new retail parks in Portugal - in Felgueiras representing an investment of €150 million cover more than 50 thousand square meters of gross area and 45 stores and among other features and “will have a significant impact on the social and economic fabric of the regions in which they are located” given the growing interest in this format” will be the largest: with a gross lettable area of ​​21,000 square meters (m2) it will have 550 parking spaces and 20 stores The opening of Felgueiras Retail Park is scheduled for the first half of 2025 and the project has eight stores a gas station and an area designated for housing comprising 104 apartments in a private condominium The Cantanhede Retail Park will appear by the end of 2025 with around 6 thousand square meters of gross leasable area The Azores Retail Park represents the group's entry into the archipelago with opening scheduled for the first quarter of 2026 “The cornerstone of this project with around 15 thousand m2 of GLA [gross leasable area] was launched on November 22nd According to the group's executive president (CEO) the need for people to shop in larger spaces with more practical entry and exit from the store Retail Mind is an Iberian management and consultancy With the UFC in town one night later for UFC 301 The main event featured a women’s strawweight showdown between Naizi Cantanhede and Yasmin Guimarães that had the potential to produce the next challenger to champ Rose Conceição Cantanhede was a perfect 7-0 to start the night and had picked up a split decision win in her promotional debut last time out was making her promotional debut on the strength of a four-fight win streak Friday, May 3, 2024 sees LFA set up shop at the Complexo Ribalta in Rio de Janeiro, Brazil. The main card airs live on UFC Fight Pass following online and dark prelims Full results from the event can be found below